Akcea Therapeutics, Inc. (AKCA): Price and Financial Metrics


Akcea Therapeutics, Inc. (AKCA)

Today's Latest Price: $14.13 USD

0.23 (1.65%)

Updated Jul 2 4:00pm

Add AKCA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

AKCA Stock Summary

  • AKCA's went public 2.97 years ago, making it older than merely 9.75% of listed US stocks we're tracking.
  • For AKCA, its debt to operating expenses ratio is greater than that reported by merely 7.98% of US equities we're observing.
  • As for revenue growth, note that AKCA's revenue has grown 61.08% over the past 12 months; that beats the revenue growth of 91.3% of US companies in our set.
  • Stocks that are quantitatively similar to AKCA, based on their financial statements, market capitalization, and price volatility, are CAPR, QUIK, MRUS, SNSS, and ATNX.
  • AKCA's SEC filings can be seen here. And to visit Akcea Therapeutics Inc's official web site, go to www.akceatx.com.
AKCA Daily Price Range
AKCA 52-Week Price Range

AKCA Stock Price Chart Technical Analysis Charts


AKCA Price/Volume Stats

Current price $14.13 52-week high $25.66
Prev. close $13.90 52-week low $8.00
Day low $13.72 Volume 207,187
Day high $14.24 Avg. volume 275,535
50-day MA $15.27 Dividend yield N/A
200-day MA $16.88 Market Cap 1.43B

Akcea Therapeutics, Inc. (AKCA) Company Bio


Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company was founded in 2014 and is based in Cambridge, Massachusetts.


AKCA Latest News Stream


Event/TimeNews Detail
Loading, please wait...

AKCA Latest Social Stream


Loading social stream, please wait...

View Full AKCA Social Stream

Latest AKCA News From Around the Web

Below are the latest news stories about Akcea Therapeutics Inc that investors may wish to consider to help them evaluate AKCA as an investment opportunity.

Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Tracy Palmer Berns has joined the company as chief compliance officer. In this role, Ms. Berns will be responsible for the company's ongoing compliance program focusing on policy development and training. She will also collaborate with other members of the executive team to provide strategic counsel related to development of business goals and compliance matters related to Akcea's commercial products and investigational therapies.

Yahoo | June 29, 2020

Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Yahoo | June 26, 2020

Evofem Biosciences (EVFM) Looks Good: Stock Adds 10.1% in Session

Evofem Biosciences (EVFM) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Yahoo | June 26, 2020

Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7%

Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

Yahoo | June 25, 2020

Kamada (KMDA) Looks Good: Stock Adds 5.7% in Session

Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Yahoo | June 25, 2020

Read More 'AKCA' Stories Here

AKCA Price Returns

1-mo -4.53%
3-mo -2.89%
6-mo -15.39%
1-year -36.44%
3-year N/A
5-year N/A
YTD -16.59%
2019 -43.80%
2018 73.62%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8407 seconds.